VYNE earnings analysis
What we found in VYNE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
VYNE's Q1 2026 results show a significant decline in revenue and increased efficiency in operating expenses compared to the prior year. Revenue dropped by 57.4% year-over-year due to reduced royalty income, while operating loss improved considerably. Despite these challenges, management remains focused on the proposed merger with Yarrow, which is expected to transform the company's future operations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Decline of 57.4% YoY
- Total revenue fell to $0.1 million from $0.2 million in Q1 2025.
- Operating Expenses Decrease by 58.5%
- Total operating expenses decreased to $3.9 million from $9.4 million in the previous year.
- Improved Loss from Continuing Operations
- Loss from continuing operations reduced to $(3.6) million from $(8.6) million, a 58.3% decrease.
- Cash and Equivalents at $24.9 Million
- The company reported cash, cash equivalents, and marketable securities of $24.9 million as of March 31, 2026.
- No Outstanding Debt
- VYNE had no debt reported as of March 31, 2026.
- Anticipation of Merger Completion
- The merger with Yarrow is expected to close in Q3 2026, contingent on stockholder approval and closing conditions.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue Dependency on Royalty Payments
- Royalty revenues fell by 57.4%, from $0.2 million in Q1 2025 to $0.1 million in Q1 2026.
- Cash Utilization Risk
- Net cash used in operating activities increased by 64.3%, from $(11.5) million in Q1 2025 to $(4.1) million in Q1 2026.
- Macroeconomic Risks Persist
- Ongoing economic uncertainty may impact financing opportunities and operational viability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-3.58
What they said about what is next.
Outlook outlined in the MD&A emphasizes the dependency on merger completion without providing numeric guidance.
The filing reads worse than the one before it.
What came before.
- 10-K · February 27, 2026
- VYNE is executing a strategic pivot via a planned merger with Yarrow Biosciences that will re-name the company to Yarrow Bioscience, Inc.; Yarrow investors purchased $100 million of Series A Preferred Stock and have…
- 10-Q · August 14, 2025
- VYNE reported Q2 revenue of $69 (royalty revenues) and a net loss of $(5,755) for the quarter (loss per share $(0.13)). Cash plus marketable securities totaled $39.6 million as of June 30, 2025 and the company reports…
- 10-Q · May 8, 2025
- VYNE reported Q1 2025 royalty revenues of $202,000 and a net loss of $8.611 million (loss per share $(0.20)). The company increased R&D spending to $6.124 million and used $11.461 million of cash in operating…
- 10-K · March 6, 2025
- VYNE is a clinical-stage biopharmaceutical company focused on BET inhibitors (InhiBET™) for immune-mediated inflammatory diseases. The Company holds exclusive worldwide rights to Tay’s BET compound library and has two…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VYNE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever